Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Cesano Alessandra reported acquisition or exercise transactions in this Form 4 filing.
PUMA Biotechnology director Alessandra Cesano reported an equity award of 27,000 shares of Common Stock on June 11, 2026. The award is in the form of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to her continued service with the company.
Following this grant, Cesano directly holds 68,850 shares. This is a compensation-related grant, not an open-market purchase.
Puma Biotechnology reported a small net loss for the first quarter of 2026 as higher research spending offset steady sales of its cancer drug NERLYNX. Total revenue was $44.8 million, slightly below $46.0 million a year earlier, as product and royalty revenue both declined modestly.
Operating costs rose to $48.6 million from $42.0 million, driven mainly by research and development expenses increasing to $19.8 million from $13.9 million. The company posted a net loss of $3.8 million, or $0.07 per share, compared with net income of $3.0 million, or $0.06 per share, in the prior-year quarter.
Despite the loss, Puma generated $15.4 million of cash from operating activities and ended the quarter with $101.5 million in cash, cash equivalents and marketable securities. Long-term debt under the Athyrium Notes was largely repaid, with $11.3 million classified as current, and stockholders’ equity stood at $128.4 million. Management believes existing cash and expected receipts from product sales and sub-license payments can fund operations for at least one year after this report.
Puma Biotechnology reported first quarter 2026 revenue of $44.8 million, slightly below $46.0 million a year earlier, as NERLYNX® net product revenue eased to $42.0 million from $43.1 million. The company posted a GAAP net loss of $3.8 million, versus net income of $3.0 million in 2025, while non-GAAP adjusted net loss was $1.9 million.
Research and development spending rose to $19.8 million, driven mainly by higher clinical trial costs for alisertib. Cash, cash equivalents and marketable securities were $101.5 million at March 31, 2026, and total debt fell to $11.3 million before being fully repaid on May 4, 2026.
Puma raised its 2026 outlook, guiding to total revenue of $222–$229 million and net income of $16–$19 million, up from prior ranges of $214–$221 million and $10–$13 million. Second quarter 2026 guidance calls for total revenue of $52–$55 million and net income of $2–$4 million, reflecting expectations for continued NERLYNX demand and ongoing alisertib development.
Puma Biotechnology, Inc. is asking stockholders to vote at its annual meeting on June 11, 2026 at its Los Angeles headquarters. Proposals include electing eight directors for one-year terms, ratifying KPMG LLP as independent auditor, and an advisory say-on-pay vote on executive compensation.
Stockholders are also asked to approve an Auerbach Warrant Amendment, extending the expiration of CEO Alan H. Auerbach’s warrant to purchase 2,116,250 common shares at $16.00 per share from October 4, 2026 to October 4, 2028. Holders of 50,891,675 outstanding common shares as of April 13, 2026 may vote in person or by proxy.